Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASCO

Share this content:
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASC
Data from pacritinib Phase 3 PERSIST-1 trial in patients with myelofibrosis to be highlighted at ASC
today announced that data from the randomized Phase 3 PERSIST-1 trial evaluating the investigational agent pacritinib in patients with myelofibrosis will be highlighted in a late-breaking oral presentation at the upcoming American Society of Clinical Oncology 2015 Meeting (May 29-June 2, 2015 in Chicago, Ill).
READ FULL ARTICLE From News Medical
Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


is free, fast, and customized just for you!

Already a member?

Sign In Now »